Monday, October 24, 2016

Norvir


Norvir is a brand name of ritonavir, approved by the FDA in the following formulation(s):


NORVIR (ritonavir - capsule; oral)



  • Manufacturer: ABBOTT

    Approval date: June 29, 1999

    Strength(s): 100MG [RLD]

NORVIR (ritonavir - solution; oral)



  • Manufacturer: ABBOTT

    Approval date: March 1, 1996

    Strength(s): 80MG/ML [RLD]

NORVIR (ritonavir - tablet; oral)



  • Manufacturer: ABBOTT LABS

    Approval date: February 10, 2010

    Strength(s): 100MG [RLD]

Has a generic version of Norvir been approved?


No. There is currently no therapeutically equivalent version of Norvir available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Norvir. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Pharmaceutical composition for inhibiting HIV protease
    Patent 5,484,801
    Issued: January 16, 1996
    Inventor(s): Al-Razzak; Laman A. & Marsh; Kennan C. & Manning; Lourdes P. & Kaul; Dilip
    Assignee(s): Abbott Laboratories
    A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a mixture of (1) (a) a solvent selected from propylene glycol and polyethylene glycol or (b) a solvent selected from polyoxyethyleneglycerol triricinoleate, polyethylene glycol 40 hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate and 2-(2-ethoxyethoxy)ethanol or (c) a mixture thereof and (2) ethanol or propylene glycol.
    Patent expiration dates:

    • January 28, 2014


    • July 28, 2014
      ✓ 
      Pediatric exclusivity




  • Retroviral protease inhibiting compounds
    Patent 5,541,206
    Issued: July 30, 1996
    Inventor(s): Kempf; Dale J. & Norbeck; Daniel W. & Sham; Hing Leung & Zhao; Chen
    Assignee(s): Abbott Laboratories
    A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
    Patent expiration dates:

    • July 30, 2013
      ✓ 
      Patent use: USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION


    • July 30, 2013
      ✓ 
      Patent use: METHOD OF USE FOR INHIBITING HIV INFECTION


    • July 30, 2013
      ✓ 
      Patent use: TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • January 30, 2014
      ✓ 
      Pediatric exclusivity




  • Retroviral protease inhibiting compounds
    Patent 5,635,523
    Issued: June 3, 1997
    Inventor(s): Kempf; Dale J. & Norbeck; Daniel W. & Sham; Hing Leung & Zhao; Chen
    Assignee(s): Abbott Laboratories
    A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
    Patent expiration dates:

    • July 30, 2013
      ✓ 
      Patent use: USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR


    • June 3, 2014
      ✓ 
      Patent use: USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR


    • July 30, 2013
      ✓ 
      Patent use: METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS


    • July 30, 2013
      ✓ 
      Patent use: TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS


    • January 30, 2014
      ✓ 
      Pediatric exclusivity


    • December 3, 2014
      ✓ 
      Pediatric exclusivity




  • Retroviral protease inhibiting compounds
    Patent 5,648,497
    Issued: July 15, 1997
    Inventor(s): Kempf; Dale J. & Norbeck; Daniel W. & Codacovi; Lynn M. & Sham; Hing L. & Wittenberger; Steven J.
    Assignee(s): Abbott Laboraotries
    A retroviral protease inhibiting compound of the formula A--X--B is disclosed. Also disclosed are a composition and method for inhibiting a retroviral protease and for treating an HIV infection. Also disclosed are processes and intermediates useful for the preparation of the retroviral protease inhibitors.
    Patent expiration dates:

    • July 15, 2014


    • July 15, 2014
      ✓ 
      Drug substance


    • January 15, 2015
      ✓ 
      Pediatric exclusivity




  • Retroviral protease inhibiting compounds
    Patent 5,674,882
    Issued: October 7, 1997
    Inventor(s): Kempf; Dale J. & Norbeck; Daniel W. & Sham; Hing Leung & Zhao; Chen
    Assignee(s): Abbott Laboratories
    A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
    Patent expiration dates:

    • July 30, 2013
      ✓ 
      Patent use: TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS


    • July 30, 2013
      ✓ 
      Patent use: TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS


    • January 30, 2014
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical composition
    Patent 5,948,436
    Issued: September 7, 1999
    Inventor(s): Al-Razzak; Laman A. & Marsh; Kennan C. & Kaul; Dilip & Manning; Lourdes P.
    Assignee(s): Abbott Laboratories
    A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a pharmaceutically acceptable alcohol. The composition can optionally comprise a pharmaceutically acceptable acid or a combination of pharmaceutically acceptable acids. The solution can optionally be encapsulated in hard gelatin capsules or soft elastic gelatin capsules. The solution can optionally be granulated with a pharmaceutically acceptable granulating agent.
    Patent expiration dates:

    • September 13, 2013
      ✓ 
      Drug product


    • September 13, 2013


    • March 13, 2014
      ✓ 
      Pediatric exclusivity




  • Method for improving pharmacokinetics
    Patent 6,037,157
    Issued: March 14, 2000
    Inventor(s): Norbeck; Daniel W. & Kempf; Dale J. & Leonard; John M. & Bertz; Richard J.
    Assignee(s): Abbott Laboratories
    A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
    Patent expiration dates:

    • June 26, 2016


    • June 26, 2016
      ✓ 
      Patent use: TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS


    • June 26, 2016
      ✓ 
      Patent use: TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS


    • December 26, 2016
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical composition
    Patent 6,232,333
    Issued: May 15, 2001
    Inventor(s): Lipari; John & Al-Razzak; Laman A. & Ghosh; Soumojeet & Gao; Rong & Kaul; Dilip
    Assignee(s): Abbott Laboratories
    A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).
    Patent expiration dates:

    • November 7, 2017


    • May 7, 2018
      ✓ 
      Pediatric exclusivity




  • Method for improving pharmacokinetics
    Patent 6,703,403
    Issued: March 9, 2004
    Inventor(s): Daniel W.; Norbeck & Dale J.; Kempf & John M.; Leonard & Richard J.; Bertz
    Assignee(s): Abbott Laboratories
    A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
    Patent expiration dates:

    • June 26, 2016
      ✓ 
      Patent use: TREATMENT OF HIV IN CONCOMITANT THERAPY


    • June 26, 2016
      ✓ 
      Patent use: TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS


    • December 26, 2016
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical formulations
    Patent 7,141,593
    Issued: November 28, 2006
    Inventor(s): Alani; Laman & Ghosh; Soumojeet
    Assignee(s): Abbott Laboratories
    Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.
    Patent expiration dates:

    • May 22, 2020
      ✓ 
      Drug product


    • November 22, 2020
      ✓ 
      Pediatric exclusivity




  • Polymorph of a pharmaceutical
    Patent 7,148,359
    Issued: December 12, 2006
    Inventor(s): Chemburkar; Sanjay R. & Patel; Ketan
    Assignee(s): Abbott Laboratories
    A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.
    Patent expiration dates:

    • July 19, 2019
      ✓ 
      Drug product


    • January 19, 2020
      ✓ 
      Pediatric exclusivity




  • Solid dispersion pharamaceutical formulations
    Patent 7,364,752
    Issued: April 29, 2008
    Inventor(s): Fort; James J. & Krill; Steven L. & Law; Devalina & Qiu; Yihong & Porter; William R. & Schmitt; Eric A.
    Assignee(s): Abbott Laboratories
    A pharmaceutical composition is disclosed which comprises a solid dispersion of an HIV protease inhibitor in a water soluble carrier, such as PEG, having enhanced bioavailability and improved dissolution properties. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersion and methods of treating an HIV infection employing said solid dispersion.
    Patent expiration dates:

    • November 10, 2020
      ✓ 
      Patent use: TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
      ✓ 
      Drug product


    • May 10, 2021
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical formulations
    Patent 7,432,294
    Issued: October 7, 2008
    Inventor(s): Alani; Laman & Ghosh; Soumojeet
    Assignee(s): Abbott Laboratories
    Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.
    Patent expiration dates:

    • May 22, 2020
      ✓ 
      Drug product


    • November 22, 2020
      ✓ 
      Pediatric exclusivity



See also...

  • Norvir Consumer Information (Drugs.com)
  • Norvir Consumer Information (Wolters Kluwer)
  • Norvir Capsules Consumer Information (Wolters Kluwer)
  • Norvir Solution Consumer Information (Wolters Kluwer)
  • Norvir Consumer Information (Cerner Multum)
  • Norvir Advanced Consumer Information (Micromedex)
  • Norvir AHFS DI Monographs (ASHP)
  • Ritonavir Consumer Information (Wolters Kluwer)
  • Ritonavir Capsules Consumer Information (Wolters Kluwer)
  • Ritonavir Solution Consumer Information (Wolters Kluwer)
  • Ritonavir Consumer Information (Cerner Multum)
  • Ritonavir Advanced Consumer Information (Micromedex)
  • Ritonavir AHFS DI Monographs (ASHP)

Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)